Ogier advises Yahong Meditech on RMB2.528 billion IPO on the Shanghai STAR Market

Ogier has acted as counsel for Jiangsu Yahong Meditech Co Ltd (Jiangsu Yahong) on its RMB2.528 billion A-shares listing on the Shanghai Stock Exchange Science and Technology Innovation Board on 7 January 2022. Ogier has provided comprehensive British Virgin Islands and Cayman Islands legal advice in connection with Jiangsu Yahong's initial public offering in the People's Republic of China.

Jiangsu Yahong issued approximately 110 million shares with CITIC Securities Co Ltd as its primary sponsor. Jiangsu Yahong is a promising pharmaceutical company in China and specialises in developing medical solutions for patients with genitourinary disorders. One of the most significant products developed by Jiangsu Yahong is ALP-1202, a ground-breaking oral anti-cancer drugs for patients suffering from genitourinary disorders.

The listing of Jiangsu Yahong manifests the commitment of Ogier to continuously support and facilitate the growth of fast-growing companies in the medical sector in China. Ogier's deal team, based in its Hong Kong office, is led by partner Cecilia Li with the support and assistance provided by from the firm's global head of Corporate, Nathan Powell, and paralegal Vicky Wu.